Negligible exposure to nifurtimox through breast milk during maternal treatment for Chagas Disease

Autores
Moroni, Samanta; Marson, María Elena; Moscatelli, Guillermo; Mastrantonio Garrido, Guido Enrique; Bisio, Margarita; González, Nicolás; Ballering, Griselda; Altcheh, Jaime; Garcia Bournissen, Facundo
Año de publicación
2019
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Background: Treatment with nifurtimox (NF) for Chagas disease is discouraged during breast-feeding because no information on NF transfer into breast milk is available. NF is safe and effective for paediatric and adult Chagas disease. We evaluated the degree of NF transfer into breast milk in lactating women with Chagas disease. Patients and methods: Prospective study of a cohort of lactating women with Chagas disease. Patients were treated with NF for 1 month. NF was measured in plasma and milk by high performance liquid chromatography (HPLC). Breastfed infants were evaluated at admission, 7th and 30th day of treatment (and monthly thereafter, for 6 months). Results: Lactating women with chronic Chagas disease (N = 10) were enrolled (median age 28 years, range 17–36). Median NF dose was 9.75 mg/kg/day three times a day (TID). Six mothers had mild adverse drug reactions (ADRs), but no ADRs were observed in any of the breastfed infants. No interruption of breastfeeding was observed. Median NF concentrations were 2.15 mg/L (Inter quartil range (IQR) 1.32–4.55) in milk and 0.30 mg/L (IQR 0.20–0.95) in plasma. Median NF milk/plasma ratio was 16 (range 8.75–30.25). Median relative infant NF dose (assuming a daily breastmilk intake of 150 mL/kg/day) was 6.7% of the maternal dose/kg/day (IQR 2.35–7.19%). Conclusions: The low concentrations of NF in breast milk and the normal clinical evaluation of the breastfed babies imply that maternal NF treatment for Chagas disease during breastfeeding is unlikely to lead to clinically relevant exposures in the breastfed infants.
Planta Piloto Multipropósito - Laboratorio de Servicios a la Industria y al Sistema Científico
Materia
Ciencias Médicas
Chagas disease
Internal medicine
Prospective cohort study
Breast milk
Breastfeeding
Blood plasma
Nifurtimox
Breast feeding
Medicine
Cohort
Gastroenterology
Nivel de accesibilidad
acceso abierto
Condiciones de uso
http://creativecommons.org/licenses/by/4.0/
Repositorio
SEDICI (UNLP)
Institución
Universidad Nacional de La Plata
OAI Identificador
oai:sedici.unlp.edu.ar:10915/126176

id SEDICI_a8295b1fb18c34c67b2153bb081390ff
oai_identifier_str oai:sedici.unlp.edu.ar:10915/126176
network_acronym_str SEDICI
repository_id_str 1329
network_name_str SEDICI (UNLP)
spelling Negligible exposure to nifurtimox through breast milk during maternal treatment for Chagas DiseaseMoroni, SamantaMarson, María ElenaMoscatelli, GuillermoMastrantonio Garrido, Guido EnriqueBisio, MargaritaGonzález, NicolásBallering, GriseldaAltcheh, JaimeGarcia Bournissen, FacundoCiencias MédicasChagas diseaseInternal medicineProspective cohort studyBreast milkBreastfeedingBlood plasmaNifurtimoxBreast feedingMedicineCohortGastroenterologyBackground: Treatment with nifurtimox (NF) for Chagas disease is discouraged during breast-feeding because no information on NF transfer into breast milk is available. NF is safe and effective for paediatric and adult Chagas disease. We evaluated the degree of NF transfer into breast milk in lactating women with Chagas disease. Patients and methods: Prospective study of a cohort of lactating women with Chagas disease. Patients were treated with NF for 1 month. NF was measured in plasma and milk by high performance liquid chromatography (HPLC). Breastfed infants were evaluated at admission, 7th and 30th day of treatment (and monthly thereafter, for 6 months). Results: Lactating women with chronic Chagas disease (N = 10) were enrolled (median age 28 years, range 17–36). Median NF dose was 9.75 mg/kg/day three times a day (TID). Six mothers had mild adverse drug reactions (ADRs), but no ADRs were observed in any of the breastfed infants. No interruption of breastfeeding was observed. Median NF concentrations were 2.15 mg/L (Inter quartil range (IQR) 1.32–4.55) in milk and 0.30 mg/L (IQR 0.20–0.95) in plasma. Median NF milk/plasma ratio was 16 (range 8.75–30.25). Median relative infant NF dose (assuming a daily breastmilk intake of 150 mL/kg/day) was 6.7% of the maternal dose/kg/day (IQR 2.35–7.19%). Conclusions: The low concentrations of NF in breast milk and the normal clinical evaluation of the breastfed babies imply that maternal NF treatment for Chagas disease during breastfeeding is unlikely to lead to clinically relevant exposures in the breastfed infants.Planta Piloto Multipropósito - Laboratorio de Servicios a la Industria y al Sistema Científico2019-08-15info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArticulohttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttp://sedici.unlp.edu.ar/handle/10915/126176enginfo:eu-repo/semantics/altIdentifier/issn/1935-2735info:eu-repo/semantics/altIdentifier/issn/1935-2727info:eu-repo/semantics/altIdentifier/pmid/31415566info:eu-repo/semantics/altIdentifier/doi/10.1371/journal.pntd.0007647info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by/4.0/Creative Commons Attribution 4.0 International (CC BY 4.0)reponame:SEDICI (UNLP)instname:Universidad Nacional de La Platainstacron:UNLP2025-09-29T11:30:23Zoai:sedici.unlp.edu.ar:10915/126176Institucionalhttp://sedici.unlp.edu.ar/Universidad públicaNo correspondehttp://sedici.unlp.edu.ar/oai/snrdalira@sedici.unlp.edu.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:13292025-09-29 11:30:24.14SEDICI (UNLP) - Universidad Nacional de La Platafalse
dc.title.none.fl_str_mv Negligible exposure to nifurtimox through breast milk during maternal treatment for Chagas Disease
title Negligible exposure to nifurtimox through breast milk during maternal treatment for Chagas Disease
spellingShingle Negligible exposure to nifurtimox through breast milk during maternal treatment for Chagas Disease
Moroni, Samanta
Ciencias Médicas
Chagas disease
Internal medicine
Prospective cohort study
Breast milk
Breastfeeding
Blood plasma
Nifurtimox
Breast feeding
Medicine
Cohort
Gastroenterology
title_short Negligible exposure to nifurtimox through breast milk during maternal treatment for Chagas Disease
title_full Negligible exposure to nifurtimox through breast milk during maternal treatment for Chagas Disease
title_fullStr Negligible exposure to nifurtimox through breast milk during maternal treatment for Chagas Disease
title_full_unstemmed Negligible exposure to nifurtimox through breast milk during maternal treatment for Chagas Disease
title_sort Negligible exposure to nifurtimox through breast milk during maternal treatment for Chagas Disease
dc.creator.none.fl_str_mv Moroni, Samanta
Marson, María Elena
Moscatelli, Guillermo
Mastrantonio Garrido, Guido Enrique
Bisio, Margarita
González, Nicolás
Ballering, Griselda
Altcheh, Jaime
Garcia Bournissen, Facundo
author Moroni, Samanta
author_facet Moroni, Samanta
Marson, María Elena
Moscatelli, Guillermo
Mastrantonio Garrido, Guido Enrique
Bisio, Margarita
González, Nicolás
Ballering, Griselda
Altcheh, Jaime
Garcia Bournissen, Facundo
author_role author
author2 Marson, María Elena
Moscatelli, Guillermo
Mastrantonio Garrido, Guido Enrique
Bisio, Margarita
González, Nicolás
Ballering, Griselda
Altcheh, Jaime
Garcia Bournissen, Facundo
author2_role author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Ciencias Médicas
Chagas disease
Internal medicine
Prospective cohort study
Breast milk
Breastfeeding
Blood plasma
Nifurtimox
Breast feeding
Medicine
Cohort
Gastroenterology
topic Ciencias Médicas
Chagas disease
Internal medicine
Prospective cohort study
Breast milk
Breastfeeding
Blood plasma
Nifurtimox
Breast feeding
Medicine
Cohort
Gastroenterology
dc.description.none.fl_txt_mv Background: Treatment with nifurtimox (NF) for Chagas disease is discouraged during breast-feeding because no information on NF transfer into breast milk is available. NF is safe and effective for paediatric and adult Chagas disease. We evaluated the degree of NF transfer into breast milk in lactating women with Chagas disease. Patients and methods: Prospective study of a cohort of lactating women with Chagas disease. Patients were treated with NF for 1 month. NF was measured in plasma and milk by high performance liquid chromatography (HPLC). Breastfed infants were evaluated at admission, 7th and 30th day of treatment (and monthly thereafter, for 6 months). Results: Lactating women with chronic Chagas disease (N = 10) were enrolled (median age 28 years, range 17–36). Median NF dose was 9.75 mg/kg/day three times a day (TID). Six mothers had mild adverse drug reactions (ADRs), but no ADRs were observed in any of the breastfed infants. No interruption of breastfeeding was observed. Median NF concentrations were 2.15 mg/L (Inter quartil range (IQR) 1.32–4.55) in milk and 0.30 mg/L (IQR 0.20–0.95) in plasma. Median NF milk/plasma ratio was 16 (range 8.75–30.25). Median relative infant NF dose (assuming a daily breastmilk intake of 150 mL/kg/day) was 6.7% of the maternal dose/kg/day (IQR 2.35–7.19%). Conclusions: The low concentrations of NF in breast milk and the normal clinical evaluation of the breastfed babies imply that maternal NF treatment for Chagas disease during breastfeeding is unlikely to lead to clinically relevant exposures in the breastfed infants.
Planta Piloto Multipropósito - Laboratorio de Servicios a la Industria y al Sistema Científico
description Background: Treatment with nifurtimox (NF) for Chagas disease is discouraged during breast-feeding because no information on NF transfer into breast milk is available. NF is safe and effective for paediatric and adult Chagas disease. We evaluated the degree of NF transfer into breast milk in lactating women with Chagas disease. Patients and methods: Prospective study of a cohort of lactating women with Chagas disease. Patients were treated with NF for 1 month. NF was measured in plasma and milk by high performance liquid chromatography (HPLC). Breastfed infants were evaluated at admission, 7th and 30th day of treatment (and monthly thereafter, for 6 months). Results: Lactating women with chronic Chagas disease (N = 10) were enrolled (median age 28 years, range 17–36). Median NF dose was 9.75 mg/kg/day three times a day (TID). Six mothers had mild adverse drug reactions (ADRs), but no ADRs were observed in any of the breastfed infants. No interruption of breastfeeding was observed. Median NF concentrations were 2.15 mg/L (Inter quartil range (IQR) 1.32–4.55) in milk and 0.30 mg/L (IQR 0.20–0.95) in plasma. Median NF milk/plasma ratio was 16 (range 8.75–30.25). Median relative infant NF dose (assuming a daily breastmilk intake of 150 mL/kg/day) was 6.7% of the maternal dose/kg/day (IQR 2.35–7.19%). Conclusions: The low concentrations of NF in breast milk and the normal clinical evaluation of the breastfed babies imply that maternal NF treatment for Chagas disease during breastfeeding is unlikely to lead to clinically relevant exposures in the breastfed infants.
publishDate 2019
dc.date.none.fl_str_mv 2019-08-15
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Articulo
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://sedici.unlp.edu.ar/handle/10915/126176
url http://sedici.unlp.edu.ar/handle/10915/126176
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/issn/1935-2735
info:eu-repo/semantics/altIdentifier/issn/1935-2727
info:eu-repo/semantics/altIdentifier/pmid/31415566
info:eu-repo/semantics/altIdentifier/doi/10.1371/journal.pntd.0007647
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
Creative Commons Attribution 4.0 International (CC BY 4.0)
eu_rights_str_mv openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by/4.0/
Creative Commons Attribution 4.0 International (CC BY 4.0)
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:SEDICI (UNLP)
instname:Universidad Nacional de La Plata
instacron:UNLP
reponame_str SEDICI (UNLP)
collection SEDICI (UNLP)
instname_str Universidad Nacional de La Plata
instacron_str UNLP
institution UNLP
repository.name.fl_str_mv SEDICI (UNLP) - Universidad Nacional de La Plata
repository.mail.fl_str_mv alira@sedici.unlp.edu.ar
_version_ 1844616184105795584
score 13.070432